Young-Suk Lim
Overview
Explore the profile of Young-Suk Lim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
317
Citations
6540
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chung S, Kim J, Choi W, Choi J, Lee D, Shim J, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39992640
Purpose: A recent trial has shown that adding transarterial chemoembolization (TACE) to lenvatinib therapy results in enhanced therapeutic efficacy in hepatocellular carcinoma (HCC). We aimed to assess the effectiveness of...
2.
Razavi H, Waked I, Qureshi H, Kondili L, Duberg A, Aleman S, et al.
J Hepatol
. 2025 Feb;
PMID: 39914746
Background And Aims: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by...
3.
Lim Y, Yu M, Choi J, Chen C, Choi W, Kang W, et al.
Lancet Gastroenterol Hepatol
. 2025 Feb;
10(4):295-305.
PMID: 39914435
Background: Current guidelines for chronic hepatitis B recommend antiviral therapy for individuals with non-cirrhotic chronic hepatitis B only if they have significant liver fibrosis or elevated alanine aminotransferase (ALT) concentrations....
4.
Park K, Lee H, Kim E, Choi W, Lee D, Shim J, et al.
Aliment Pharmacol Ther
. 2025 Jan;
PMID: 39871662
Background And Aims: Real-world data on the variceal bleeding (VB) risk in patients receiving atezolizumab-bevacizumab (Atezo-Bev) treatment remain limited. This study aimed to assess the risk of VB and identify...
5.
Wu D, Kao J, Piratvisuth T, Wang X, Kennedy P, Otsuka M, et al.
Clin Mol Hepatol
. 2025 Jan;
PMID: 39838828
As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional...
6.
Jang S, Kim G, Lim Y, Kim H, Lee E
Am J Transplant
. 2025 Jan;
PMID: 39826891
The potential of everolimus (EVR) in reducing hepatocellular carcinoma (HCC) among recipients following liver transplantation has been reported. This nationwide population-based quasi-cohort study investigated whether combining EVR with calcineurin inhibitor...
7.
Chung S, Kim Y, Lim J, Choi J, Lee D, Shim J, et al.
Am J Gastroenterol
. 2024 Dec;
PMID: 39718241
Introduction: Nationwide, population-based data on the risk of extrahepatic malignancy in patients with autoimmune hepatitis (AIH) in Asian countries are scarce. This study aimed to examine the risk of developing...
8.
9.
Song Y, Jung J, Park J, Kim S, Choi J, Lee D, et al.
J Med Imaging Radiat Oncol
. 2024 Oct;
69(1):144-152.
PMID: 39428124
Introduction: We investigated the clinical outcomes of stereotactic body radiation therapy (SBRT) alone versus SBRT after incomplete transarterial chemoembolization (TACE) for a single recurrent hepatocellular carcinoma (HCC) smaller than 5 ...
10.
Yuen M, Lim Y, Yoon K, Lim T, Heo J, Tangkijvanich P, et al.
Lancet Gastroenterol Hepatol
. 2024 Oct;
9(12):1121-1132.
PMID: 39389081
Background: Chronic hepatitis B virus (HBV) remains a global concern, with current treatments achieving low rates of HBsAg seroclearance. VIR-2218 (elebsiran), a small interfering RNA agent against HBV transcripts, reduces...